Corporate Symposia
Corporate Lunch Symposium 1: CarThera
Overcoming barriers: Ultrasound and the BBB
Friday, September 20, 13:05 - 14:20 hrs
Room: Bellecour
Chairs: Jean-Yves Delattre (Paris, FR), Roger Stupp (Chicago, US)
| 13:05 – 13:10 | Introduction |
| Jean-Yves Delattre (Paris, FR) | |
| 13:10 – 13:25 | Efficiently tailoring local brain tumor therapy - challenges and surgical perspectives |
| Jörg Tonn (Munich, DE) | |
| 13:25 – 13:40 | Ultrasound based BBB Opening and results of phase 1 trial |
| Alexandre Carpentier (Paris, FR) | |
| 13:40 – 13:55 | Overcoming challenges in treating brain tumors |
| John De Groot (Houston, US) | |
| 13:55 – 14:10 | Summary review & perspectives |
| Roger Stupp (Chicago, US) | |
| 14:10- 14:20 | Q&A to speakers and Ahmed Idbaih (Paris, FR), principal investigator |
Corporate Lunch Workshop 1: Illumina
DNA Methylation Profiling as a tool for Classifying Brain Tumors
Friday, September 20, 13:05 - 14:20 hrs
Room: Tête d'Or 1
| 13:05 – 13:15 | Welcome |
| Aida Soler (Madrid, ES) - Sr Segment Marketing Manager – Cancer Research, Illumina | |
| 13:15 – 14:05 | DNA Methylation Profiling as a tool for Classifying Brain Tumors |
| Felix Sahm (Heidelberg, DE) | |
| 14:05 – 14:20 | Question and Answers |
DNA methylation has proven to reliably identify tumor entities and even separate subgroups within entities that cannot be distinguished by histological evaluation. A joint effort of teams in Heidelberg and international collaborators has resulted in a machine learning-based algorithm that employs DNA methylation data to allot tumor specimen to the respective entity. Additionally, copy-number-variations are derived from the methylation data, informing about potentially relevant alterations. Application of this tool on ten-thousands of samples now also allows for identification of novel, so far unrecognized entities. The symposium will summarize the biological background of the approach, development and practical implementation of the classifier tool, and implications of ongoing research in this field.
Corporate Lunch Symposium 2: AbbVie Inc
Biomarkers and Therapies in GBM - What we have learned and what is new
Saturday, September 21, 12:45 - 14:00 hrs
Room: Bellecour
Chairs: Andreas von Deimling (Heidelberg, DE), Marc Sanson (Paris, FR), Martin van den Bent (Rotterdam, NL)
| 13:00 – 13:05 | Welcome and introduction |
| Marc Sanson (Paris, FR) | |
| 13:05 - 13:25 | Biomarkers in GBM |
| Andreas van Deimling (Heidelberg, DE) | |
| 13:25 - 13:45 | Therapies for GBM: Lessons learned and new developments |
| Martin van den Bent (Rotterdam, NL) | |
| 13:45 - 14:00 | Panel discussion |
Corporate Symposium 3: Bristol-Myers Squibb
New Horizons for Immuno-Oncology and MGMT methylation in Glioblastoma
Saturday, September 21, 17:15 - 18:00 hrs
Room: Bellecour
Chairs: Michael Lim (Baltimore, US), Michael Weller (Zurich, CH)
17:15 – 17:25 | Understanding of glioblastoma biology and MGMT promoter methylation as a biomarker – implications for management |
Michael Weller | |
17:25 – 17:35 | Immuno-oncology for treatment of GBM – current state |
Michael Weller | |
17:35 – 17:45 | Emerging findings in glioblastoma biology – strategies to overcome the immunosuppressive environment |
Michael Lim | |
17:45 – 17:55 | Immuno-oncology for treatment of GBM – Novel approaches |
| Michael Lim |